

Contents

1	Organic Synthesis in Drug Discovery and Development	1
1.1	Introduction	1
1.2	Synthetic Organic Chemistry in Pharmaceutical R&D	2
1.3	New Concepts in the Drug Discovery Process	5
1.3.1	The Impact of Natural Products on Modern Drug Discovery	6
1.3.2	Biologically Orientated Synthesis in Drug Discovery	8
1.3.3	Incorporation of Genomics and DNA-templated Synthesis into Drug Discovery	9
1.4	Conclusion	11
	References	11
2	Aliskiren Fumarate	13
2.1	Introduction	13
2.2	Renin and the Mechanism of Action of Aliskiren	14
2.3	Structural Characteristics and Synthetic Approaches to Aliskiren	16
2.3.1	Strategy Based on Visual Imagery, Starting from Nature's Chiral Pool: A Dali-Like Presentation of Objects	18
2.3.2	Fine-Tuning of the Chiral Ligand for the Rh Complex: Hydrogenation of the Selected Substrate with Extreme Enantioselectivities	21
2.4	Conclusion	26
	References	26
3	(R)-K-13675	29
3.1	Introduction	29
3.2	Peroxisome Proliferator-Activated Receptor α Agonists	29
3.2.1	β -Phenylpropionic Acids	30
3.2.2	α -Alkoxy- β -Arylpropionic Acids	31
3.2.3	α -Aryloxy- β -Phenyl Propionic Acids	33
3.2.4	Oxybenzoylglycine Derivatives	34
3.3	Non-hydrolytic Anomalous Lactone Ring-Opening	35

3.4 Mitsunobu Reaction in the Ether Bond Formation	38
3.5 Conclusion.....	42
References.....	42
4 Sitagliptin Phosphate Monohydrate	45
4.1 Introduction.....	45
4.2 Endogenous Glucoregulatory Peptide Hormones and Dipeptidyl Peptidase IV (DPP4) Inhibitors	46
4.3 Synthesis with C-acyl Meldrum's Acid as the <i>N</i> -Acyating Agent	47
4.4 Highly Enantioselective Hydrogenation of Unprotected β -Enamino Amides and the Use of Josiphos-Ligands.....	50
4.5 Ammonium Chloride, an Effective Promoter of Catalytic Enantioselective Hydrogenation	52
4.6 Conclusion.....	53
References.....	53
5 Biaryl Units in Valsartan and Vancomycin	55
5.1 Introduction.....	55
5.2 Angiotensin AT1 Receptor, a G-Protein-Coupled Receptor	56
5.3 Cu-Promoted Catalytic Decarboxylative Biaryl Synthesis, a Biomimetic Type Aerobic Decarboxylation	59
5.4 Stereoselective Approach to the Axially Chiral Biaryl System; the Case of Vancomycin	63
5.5 Conclusion.....	67
References.....	67
6 3-Amino-1,4-Benzodiazepines	69
6.1 Introduction.....	69
6.2 3-Amino-1,4-Benzodiazepine Derivatives as γ -Secretase Inhibitors...	70
6.3 Configurational Stability: Racemization and Enantiomerization.....	71
6.4 Crystallization Induced Asymmetric Transformation	73
6.5 Asymmetric Ireland–Claisen Rearrangement.....	74
6.6 Hydroboration of the Terminal C=C Bond: Anti-Markovnikov Hydratation	76
6.7 Crystallization-Induced Asymmetric Transformation in the Synthesis of L-768,673.....	79
6.8 Conclusion.....	81
References.....	81
7 Sertraline	83
7.1 Introduction	83
7.2 Synaptosomal Serotonin Uptake and Its Selective Inhibitors (SSRI)	84
7.3 Action of Sertraline and Its Protein Target.....	85

7.4	General Synthetic Route	86
7.5	Stereoselective Reduction of Ketones and Imines Under Kinetic and Thermodynamic Control	87
7.5.1	Diastereoselectivity of Hydrogenation of rac-tetralone-Methylimine: The Old (MeNH ₂ /TiCl ₄ /Toluene) Method Is Improved by Using MeNH ₂ /EtOH-Pd/CaCO ₃ , 60–65°C in a Telescoped Process	87
7.5.2	Kinetic Resolution of Racemic Methylamine: Hydrosilylation by (R,R)-(EBTHI)TiF ₂ /PhSiH ₃ Catalytic System	88
7.5.3	Catalytic Epimerization of the <i>Trans</i> - to the <i>Cis</i> -Isomer of Sertraline	90
7.5.4	Stereoselective Reduction of Tetralone by Chiral Diphenyloxazaborolidine.....	91
7.6	Desymmetrization of Oxabenzonorbornadiene, Suzuki Coupling of Arylboronic Acids and Vinyl Halides	92
7.7	Pd-Catalyzed (Tsuji-Trost) Coupling of Arylboronic Acids and Allylic Esters	94
7.8	Simulated Moving Bed in the Commercial Production of Sertraline	97
7.9	Conclusion	101
	References.....	101
8	1,2-Dihydroquinolines	105
8.1	Introduction.....	105
8.2	Glucocorticoid Receptor	106
8.3	Asymmetric Organocatalysis: Introducing a Thiourea Catalyst for the Petasis Reaction	107
8.3.1	General Consideration of the Petasis Reaction	108
8.3.2	Catalytic, Enantioselective Petasis Reaction.....	111
8.4	Multi-component Reactions: General Concept and Examples	114
8.4.1	General Concept of Multi-component Reactions.....	114
8.4.2	Efficient, Isocyanide-Based Ugi Multi-component Reactions ...	115
8.5	Conclusion.....	117
	References.....	117
9	(–)-Menthol	119
9.1	Introduction.....	119
9.2	Natural Sources and First Technological Production of (–)-Menthol	120
9.3	Enantioselective Allylic Amine–Enamine–Imine Rearrangement, Catalysed by Rh(I)-(–)-BINAP Complex	121
9.4	Production Scale Synthesis of Both Enantiomers	124
9.5	Conclusion.....	125
	References.....	125

10 Fexofenadine Hydrochloride	127
10.1 Introduction	127
10.2 Histamine Receptors as Biological Targets for Anti-allergy Drugs	128
10.3 Absolute Configuration and “Racemic Switch”	129
10.4 Retrosynthetic Analysis of Fexofenadine	131
10.4.1 ZnBr ₂ -Catalyzed Rearrangement of α -Haloketones to Terminal Carboxylic Acids	133
10.4.2 Microbial Oxidation of Non-activated C–H Bond	137
10.4.3 Bioisosterism: Silicon Switch of Fexofenadine to Sila-Fexofenadine	139
10.5 Conclusion	141
References	141
11 Montelukast Sodium	143
11.1 Introduction	143
11.2 Leukotriene D ₄ Receptor (LTD ₄), CysLT-1 Receptor Antagonists	144
11.3 Hydroboration of Ketones with Boranes from α -Pinenes and the Non-linear Effect in Asymmetric Reactions	146
11.4 Ru(II) Catalyzed Enantioselective Hydrogen Transfer	150
11.5 Biocatalytic Reduction with Ketoreductase KRED (KetoREDuctase)	152
11.6 CeCl ₃ -THF Solvate as a Promoter of the Grignard Reaction: Phase Transfer Catalysis	152
11.7 Conclusion	154
References	155
12 Thiolactone Peptides as Antibacterial Peptidomimetics	157
12.1 Introduction	157
12.2 Virulence and Quorum-Sensing System of <i>Staphylococcus</i> <i>aureus</i>	158
12.3 Development of Chemical Ligation in Peptide Synthesis	160
12.4 Development of Native Chemical Ligation; Chemoselectivity in Peptide Synthesis	162
12.5 Development of NCL in Thiolactone Peptide Synthesis	165
12.6 Conclusion	169
References	169
13 Efavirenz	171
13.1 Introduction	171
13.2 HIV-1 Reverse Transcriptase Inhibitors	172
13.2.1 Steric Interactions at the Active Site	173

13.3	Asymmetric Addition of Alkyne Anion to C=O Bond with Formation of Chiral Li ⁺ Aggregates.....	175
13.3.1	Mechanism of the Chirality Transfer.....	175
13.3.2	Equilibration of Lithium Aggregates and the Effect of Their Relative Stability on Enantioselectivity.....	177
13.4	Scale-up of Alkynylation Promoted by the Use of Et ₂ Zn.....	178
13.5	Conclusion	179
	References.....	179
14	Paclitaxel	181
14.1	Introduction	181
14.2	Disturbed Dynamics of Cellular Microtubules by Binding to β -Tubulin.....	182
14.3	Three Selected Synthetic Transformations on the Pathway to Paclitaxel	183
14.3.1	Intramolecular Heck Reaction on the Synthetic Route to Baccatin III.....	184
14.3.2	Trifunctional Catalyst for Biomimetic Synthesis of Chiral Diols: Synthesis of the Paclitaxel Side-Chain....	187
14.3.3	Zr-Complex Catalysis in the Reductive N-deacylation of Taxanes to the Primary Amine, the Key Precursor of Paclitaxel	194
14.4	Conclusion	196
	References.....	196
15	Neoglycoconjugate	199
15.1	Introduction	199
15.2	Human α -1,3-Fucosyltransferase IV (Fuc-T).....	200
15.3	Click Chemistry: Energetically Preferred Reactions	202
15.4	Target-Guided Synthesis or Freeze-Frame Click Chemistry.....	204
15.5	Application of Click Chemistry to the Synthesis of Neoglycoconjugate 1.....	207
15.6	Conclusion	209
	References.....	209
16	12-Aza-Epothilones	211
16.1	Introduction	211
16.2	Epothilones: Mechanism of Action and Structure–Activity Relationships.....	212
16.3	Extensive vs. Peripheral Structural Modifications of Natural Products	214
16.4	Ring Closure Metathesis: An Efficient Approach to Macrocyclic “Non-natural Natural Products”	215

16.5 Diimide Reduction of the Allylic C=C Bond	222
16.6 Conclusion	224
References.....	224
Synthetic Methods and Concepts Discussed in the Chapters	227
Index	231

Signposts to Chiral Drugs
Organic Synthesis in Action
Sunjic, V.; Parnham, M.J.
2011, XX, 232 p., Hardcover
ISBN: 978-3-0348-0124-9